Nektar Therapeutics NKTR
Find similar stocks with Morningstar Investor.
Morningstar analysts do not currently cover NKTR, but with our powerful screener, you can find
stocks in the same sector,industry, or style and filter on our unbiased ratings and valuation metrics.
News
-
Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024
-
Nektar Management to Present at Upcoming Investor Conferences
-
Nektar Therapeutics Reports Second Quarter 2024 Financial Results
-
Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets
Trading Information
- Previous Close Price
- $1.30
- Day Range
- $1.29–1.37
- 52-Week Range
- $0.41–1.93
- Bid/Ask
- $1.15 / $1.32
- Market Cap
- $242.98 Mil
- Volume/Avg
- 786,452 / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.78
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 137
- Website
- https://www.nektar.com
Comparables
Valuation
|
Metric
|
NKTR
|
CGON
|
MGNX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.05 | 4.42 | 3.89 |
Price/Sales | 2.78 | 244.06 | 5.66 |
Price/Cash Flow | — | — | — |
Price/Earnings
NKTR
CGON
MGNX
Financial Strength
|
Metric
|
NKTR
|
CGON
|
MGNX
|
|---|---|---|---|
Quick Ratio | 4.78 | 46.66 | 2.53 |
Current Ratio | 5.15 | 47.57 | 2.71 |
Interest Coverage | −6.88 | — | −128.87 |
Quick Ratio
NKTR
CGON
MGNX
Profitability
|
Metric
|
NKTR
|
CGON
|
MGNX
|
|---|---|---|---|
Return on Assets (Normalized) | −29.37% | −15.24% | −59.21% |
Return on Equity (Normalized) | −87.80% | −26.61% | −120.96% |
Return on Invested Capital (Normalized) | −44.64% | −25.60% | −102.88% |
Return on Assets
NKTR
CGON
MGNX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Lnsnptqyx | Xnwt | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Kldgvlwnn | Pfpms | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zxmhkvfg | Plsxkz | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Lxjppkgr | Hjgxzx | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Ydsgfcd | Zqxzg | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Rzjmwtt | Fbjz | $29.2 Bil | |||
| Moderna Inc
MRNA
| Xdnzmnlq | Vmtl | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Scdkvtt | Fvhl | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mltjclbrc | Xzgzxx | $13.2 Bil | |||
| Incyte Corp
INCY
| Nrrvqtk | Rwvvbm | $13.0 Bil |
United States